TrialFrontiers in immunology2024

Icanbelimod (CBP-307), a next-generation Sphingosine-1-phosphate receptor modulator, in healthy men: pharmacokinetics, pharmacodynamics, safety, and tolerability in a randomized trial in Australia.

Jason Lickliter et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.